Damora Therapeutics Inc. (DMRA)
NASDAQ: DMRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DMRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.44B
- P/E (TTM)
- 13.58
- EPS (TTM)
- $1.71
- Dividend yield
- None
- 52-week range
- 15.76 – 38.33
- Day range
- 23.13 – 24.51
- Volume / Avg
- 643.38K / 584.28K
- Beta
- —
- Shares outstanding
- 61.90M
52-week range
DMRA stock today
Damora Therapeutics (DMRA) closed at $23.22 on Nov 20, down 4.44% (-$1.08), versus the S&P 500's 3.70% decline. At this level, DMRA sits in the middle of its 52-week range of $15.76 to $38.33: 39.4% below the high, set on Dec 26, 2025 and 47.3% above the low. DMRA is up 0.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 38.5%.
At 13.6x trailing earnings, Damora Therapeutics trades above the peer-group median of 7.2x.
Summary generated from market data by MetaCap's automated system. Methodology
About Damora Therapeutics
Company profileDamora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Jennifer A. Jarrett M.B.A.
- Headquarters
- Waltham, MA
- Employees
- 7
- IPO year
- 2020
- Website
- damoratx.com
Financial highlights
Full financialsDamora Therapeutics reported a net loss of $209.8 million, compared with a loss of $21.4 million a year earlier. Diluted earnings per share came in at $3.98.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-209.84M | $-21.44M | $-38.35M | $-61.62M | $-51.75M |
| EPS (diluted) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$46.78+101.46%
- Strong buy 1
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.40 vs $-0.52
- Surprise
- +23.08%
DMRA news
All DMRA newsDamora Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KLRAKailera Therapeutics Inc. | 11.02 | -4.84% | $1.43B | vs DMRA |
| SRPTSarepta Therapeutics Inc. | 13.33 | -5.93% | $1.43B | vs DMRA |
| ADRXADARx Pharmaceuticals Inc. | 12.79 | -9.68% | $1.42B | vs DMRA |
| NRIXNurix Therapeutics Inc. | 12.85 | -5.55% | $1.40B | vs DMRA |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs DMRA |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs DMRA |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs DMRA |
| PGENPrecigen Inc. | 4.21 | +1.20% | $1.51B | vs DMRA |
Indexes, lists and sector
Damora Therapeutics stock FAQ
What is Damora Therapeutics's stock price today?
DMRA last traded at $23.22 as of Nov 20, 4:00 PM EST, down 4.44% on the day. Prices are delayed at least 15 minutes.
Does Damora Therapeutics pay a dividend?
No. Damora Therapeutics does not currently pay a regular cash dividend.
What is DMRA's P/E ratio?
DMRA trades at a trailing P/E ratio of 13.58, compared with a median of 7.2 for its closest peers.
Who is Damora Therapeutics's CEO?
Ms. Jennifer A. Jarrett M.B.A. is the chief executive officer of Damora Therapeutics Inc., which has about 7 employees.
Has DMRA ever split its stock?
Yes. The most recent DMRA stock split was a 1-for-25 split on Aug 30, 2024.
What is the DMRA 52-week high?
The 52-week high for DMRA is $38.33 and the 52-week low is $15.76. The stock is currently 39.4% below its high.